On the Frontlines of Psoriasis

Unlocking the Potential of TYK2 Inhibitors in Plaque Psoriasis

15 min · 16. jan. 2026
episode Unlocking the Potential of TYK2 Inhibitors in Plaque Psoriasis cover

Beskrivelse

Guest: Christopher Bunick, MD, PhD, FAAD Host: Ryan Quigley With high selectivity, durable response, and once-daily dosing, next-generation TYK2 inhibitors offer a promising oral option for patients with moderate-to-severe plaque psoriasis. Ryan Quigley sits down with Dr. Christopher Bunick, Associate Professor of Dermatology and Translational Biomedicine at Yale University School of Medicine, to learn more about how these agents may align with evolving patient preferences and expand options beyond injectables.

Kommentarer

0

Vær den første til å kommentere

Registrer deg nå og bli medlem av On the Frontlines of Psoriasis sitt community!

Prøv gratis

Prøv gratis i 14 dager

99 kr / Måned etter prøveperioden. · Avslutt når som helst.

  • Eksklusive podkaster
  • 20 timer lydbøker i måneden
  • Gratis podkaster

Alle episoder

28 Episoder